Literature DB >> 10482023

Pseudomonas aeruginosa bacteremia in patients infected with human immunodeficiency virus type 1.

F Vidal1, J Mensa, J A Martínez, M Almela, F Marco, J M Gatell, C Richart, E Soriano, M T Jiménez de Anta.   

Abstract

A prospective analysis of 43 episodes of Pseudomonas aeruginosa bacteremia in HIV-1-infected subjects was performed and the results compared with the incidence and outcome of Pseudomonas aeruginosa bacteremia in other high-risk patients, such as transplant recipients, leukemia patients, or patients hospitalized in the intensive care unit. The incidence of bacteremia/fungemia as a whole and of gram-negative and Pseudomonas aeruginosa bacteremia in particular was greater in HIV-1-infected subjects than in the unselected general population admitted. In contrast, the incidence of Pseudomonas aeruginosa bacteremia in HIV-1-infected patients did not differ from that in patients with other high-risk conditions. In patients with HIV-1 infection, independent risk factors for presenting Pseudomonas aeruginosa bacteremia were nosocomial origin (OR, 2.7; 95% CI, 1.3-5.7), neutropenia (OR, 2.7; 95% CI, 1.07-6.8), previous treatment with cephalosporins (OR, 3.6; 95% CI, 1.1-11.6), and a CD4+ cell count lower than 50 cells/mm3 (OR, 3.1; 95% CI, 1.7-8.6). Primary bacteremia and pneumonia were the most common forms of presentation. Fourteen (33%) patients died as a consequence of the bacteremia. The presence of severe sepsis (OR, 17.5; 95% CI, 3.2-68) and the institution of inappropriate definitive antibiotic therapy (OR, 2.7; 95% CI, 1.1-13) were independently associated with a poor outcome. One year after the development of bacteremia, only eight (19%) patients remained alive.

Entities:  

Mesh:

Year:  1999        PMID: 10482023     DOI: 10.1007/s100960050326

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  10 in total

1.  Role of macrophage chemoattractant protein-1 in acute inflammation after lung contusion.

Authors:  Madathilparambil V Suresh; Bi Yu; David Machado-Aranda; Matthew D Bender; Laura Ochoa-Frongia; Jadwiga D Helinski; Bruce A Davidson; Paul R Knight; Cory M Hogaboam; Bethany B Moore; Krishnan Raghavendran
Journal:  Am J Respir Cell Mol Biol       Date:  2012-01-26       Impact factor: 6.914

2.  Acquisition of resistant microorganisms and infections in HIV-infected patients admitted to the ICU.

Authors:  N Cobos-Trigueros; M Rinaudo; M Solé; P Castro; J Pumarol; C Hernández; S Fernández; J M Nicolás; J Mallolas; J Vila; L Morata; J M Gatell; A Soriano; J Mensa; J A Martínez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-10-23       Impact factor: 3.267

Review 3.  The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections.

Authors:  James A Driscoll; Steven L Brody; Marin H Kollef
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 4.  Pathogen-host interactions in Pseudomonas aeruginosa pneumonia.

Authors:  Ruxana T Sadikot; Timothy S Blackwell; John W Christman; Alice S Prince
Journal:  Am J Respir Crit Care Med       Date:  2005-02-01       Impact factor: 21.405

5.  Sepsis is a major determinant of outcome in critically ill HIV/AIDS patients.

Authors:  André M Japiassú; Rodrigo T Amâncio; Emerson C Mesquita; Denise M Medeiros; Helena B Bernal; Estevão P Nunes; Paula M Luz; Beatriz Grinsztejn; Fernando A Bozza
Journal:  Crit Care       Date:  2010-08-10       Impact factor: 9.097

6.  Role of granulocyte macrophage colony-stimulating factor during gram-negative lung infection with Pseudomonas aeruginosa.

Authors:  Megan N Ballinger; Robert Paine; Carlos H C Serezani; David M Aronoff; Esther S Choi; Theodore J Standiford; Galen B Toews; Bethany B Moore
Journal:  Am J Respir Cell Mol Biol       Date:  2006-02-10       Impact factor: 6.914

7.  Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas aeruginosa bacteremia.

Authors:  Ioannis A Bliziotis; Nicola Petrosillo; Argyris Michalopoulos; George Samonis; Matthew E Falagas
Journal:  PLoS One       Date:  2011-10-26       Impact factor: 3.240

8.  Intoxication of host cells by the T3SS phospholipase ExoU: PI(4,5)P2-associated, cytoskeletal collapse and late phase membrane blebbing.

Authors:  Hiromi Sato; Dara W Frank
Journal:  PLoS One       Date:  2014-07-25       Impact factor: 3.240

9.  Evaluation of Phage Therapy for Pulmonary Infection of Mouse by Liquid Aerosol-Exposure Pseudomonas aeruginosa.

Authors:  Yajun Zhang; Biao Meng; Xiao Wei; Yan Li; Xiaohui Wang; Yan Zheng; Changjun Wang; Lihong Cui; Xiangna Zhao
Journal:  Infect Drug Resist       Date:  2021-10-27       Impact factor: 4.003

10.  Bacteremia in hospitalized patients with human immunodeficiency virus: A prospective, cohort study.

Authors:  B Afessa; I Morales; B Weaver
Journal:  BMC Infect Dis       Date:  2001-09-07       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.